This study examines the long-term safety of a drug called secukinumab for treating polymyalgia rheumatica (PMR), a condition that causes muscle pain and stiffness. The study lasts up to 2 years and includes regular visits for check-ups and medication resupply. Participants will first have a 4-week screening. Then, during the first 24 weeks, they'll visit the study site every 4 weeks, and every 12 weeks after that for the rest of the study. At the end, there's a 16-week follow-up period without treatment.

• Study lasts up to 2 years with regular visits every 4 to 12 weeks.
• Participants must have completed a previous related study and not used rescue treatment.
• Potential benefits must outweigh risks based on doctor's judgment.

To join, participants should not have certain infections like HIV or hepatitis, nor recent cancer. Some vaccines are also restricted before joining the study. Doctors will ensure it's safe for each person to participate.